The ALS Therapy Development Institute (ALS TDI) is the Drug Discovery Engine for ALS. Here’s how we are working to fuel the ALS clinical pipeline.

 

We Don’t Just Focus on One Treatment. We Build a Pipeline.

  • In 2022, our preclinical research has continued to fuel the pipeline by conducting in-vivo screens of more than 20 potential drug candidates. The treatments that show the most promise will be further advanced.
  • While this screening is ongoing, two of the most promising discoveries that have emerged from our research - Type I PRMT inhibitors and copper complexes - have continued to advance toward trials.
 

We Don’t Just Gather Data. We Apply It.

  • In collaboration with Google, we applied data from our ALS Research Collaborative (ARC) and machine learning to develop new digital biomarkers of ALS – tools that can objectively measure ALS symptom progression over time.
  • These tools could potentially provide researchers and clinicians with more accurate ways to track progression and measure the effectiveness of treatments.
  • Researchers and participants in the ARC study have access to these tools today.
 

We Don’t Just Propose Solutions. We Build Them.

  • ALS TDI has built a multifaceted program to collect and share comprehensive data about ALS.
  • This includes a cloud-based platform that researchers and institutes worldwide will use to access our PMP’s extensive natural history data about ALS.
  • By sharing this dataset with other researchers we aim to improve the understanding of ALS patient subsets and inform the discovery of more targets for drugs.
  • The project is undergoing beta testing and will be fully launched in Q1 of 2023.
 

We Don’t Just Collect Samples. We Use Them.

  • Utilizing a $281,000 grant from the ALS Research Program (ALSRP) at the Department of Defense, we are deploying samples collected from participants in the ARC study to identify new biomarkers and targets for ALS.
  • Leveraging this dataset from ARC and cutting-edge proteomics technology, this study represents an unprecedented opportunity in the pursuit of ALS biomarkers.
 

We Don’t Stop.We Boldly Move Forward

  • On May 31, 2022, Eledon Pharmaceuticals announced that tegoprubart—a drug developed at ALS TDI—successfully completed a phase 2a clinical trial.
  • The advancement of tegoprubart represents tremendous promise and progress, but we are not done. We continue to work tirelessly to move the next drugs into trials.

 

With your support, we will not stop until everyone with ALS has effective treatment options.

 

What to do next?